Prima BioMed Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Sydney Australia (2001)
Status: Acquired by Immutep S.A. (2014)

Organization Overview

First Clinical Trial
None
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
None

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (2)

Key: Prima BioMed (0) Acquired (2)

eftilagimod alpha (4 trials)

paclitaxel (taxol) (3 trials)

Drugs in Phase 2 Trials (5)

Key: Prima BioMed (0) Acquired (5)

8 melanoma-specific peptides (1 trial)

cvac (3 trials)

lag-3 (7 trials)

muc1 dendritic cell vaccine (1 trial)

pembrolizumab (keytruda) (4 trials)

Drugs in Phase 1 Trials (2)

Key: Prima BioMed (0) Acquired (2)

hepatitis b vaccine (recombinant) (Recombivax) (1 trial)

sodium chloride (1 trial)

Indications

Overview

  • Highest Phase: None
  • # of Trials: 17
  • # of Trial APIs: 9